FIELD: pharmaceuticals.
SUBSTANCE: invention relates to compounds of the Formula:
wherein m is 0, 1, or 2; n is 0, 1, or 2; XA is-O -; ring B is phenyl, naphthyl, or quinolinyl; Ring C is phenyl or thiophenyl; R1 is selected from hydroxyl and -O(С1-С6alkyl); R2 is selected from
-СН=СНСООН, -NH(CO)COOH and -СООН; R3 is independently selected in each case from hydrogen, halogen and C1-С6alkyl and R4 is independently selected in each case from hydrogen, halogen, hydroxyl, C1-С6alkyl, C1-С6fluoroalkyl and -O(C1-С6fluoroalkyl), or its pharmacologically acceptable salts, which are estrogen receptor blockers, and their use for treatment of estrogen-related diseases.
EFFECT: estrogen receptor blockers are proposed that can be used in estrogen-related disease treatment.
44 cl, 10 dwg, 4 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788174C2 |
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788163C2 |
| BENZAMIDE COMPOUNDS | 2019 |
|
RU2801647C2 |
| COMBINATION THERAPY USING DIARYL MACROCYCLIC COMPOUNDS | 2018 |
|
RU2784853C2 |
| PYRROLOPYRIMIDINE COMPOUNDS FOR MALIGNANT TUMOUR TREATMENT | 2012 |
|
RU2631655C2 |
| COMPOSITIONS AND METHODS OF TREATING DISEASES AND CONDITIONS | 2015 |
|
RU2713886C2 |
| METHODS FOR TREATMENT OF MALIGNANT TUMORS, USING ATR INHIBITOR | 2018 |
|
RU2813966C2 |
| COMPOSITIONS BASED ON SHP2 INHIBITOR AND METHODS OF CANCER TREATMENT | 2018 |
|
RU2805355C2 |
| COMBINATION THERAPY USING CC CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE CHECKPOINT INHIBITORS | 2019 |
|
RU2810717C2 |
| POINT MUTATIONS IN TRK INHIBITOR-RESISTANT MALIGNANT TUMORS AND RELATED METHODS | 2016 |
|
RU2744852C2 |
